Leerink Partners Reiterates a Buy Rating on Geron Corporation (GERN) - MSN
3 days ago • Google News
Geron Corporation (GERN)
US$ 1.412.18%
Price Chart
Key Statistics
Market Cap
$ 878.95M
P/E Ratio
0.00
Revenue (TTM)
$ 116.29M
Volume
13.36M
52W High
$ 5.06
52W Low
$ 1.17
Dividend Yield
0.00%
Beta
0.68
Technicals
50-Day MA
1.4306
200-Day MA
2.6554
52 Week High
5.06
52 Week Low
1.17
About GERN
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult pat.
Employees
229
Headquarters
Foster City, CA
CEO
Ms. Dawn Carter Bir
Latest News
Geron's 5.4% Surge: A Technical Catalyst or Sector Momentum? - AInvest
Yesterday • Google News
Why Geron Corporation (GERN) Is The Best Low Priced Biotech Stock to Buy Now - Yahoo Finance
2025-05-13 • Google News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg